International audienceBackground and objective - Dose-finding, aiming at finding the maximum tolerated dose, and pharmacokinetics studies are the first in human studies in the development process of a new pharmacological treatment. In the literature, to date only few attempts have been made to combine pharmacokinetics and dose-finding and to our knowledge no software implementation is generally available. In previous papers, we proposed several Bayesian adaptive pharmacokinetics-based dose-finding designs in small populations. The objective of this work is to implement these dose-finding methods in an R package, called dfpk.Methods - All methods were developed in a sequential Bayesian setting and Bayesian parameter estimation is carried out...
Bayesian estimation of pharmacokinetic parameters (PKP), as discussed in this review, provides a pow...
We consider the problem of how to efficiently and safely design dose finding studies. Both current a...
Biopharmaceuticals, especially monoclonal antibodies, have been increasingly used to treat several c...
International audienceBackground and objective - Dose-finding, aiming at finding the maximum tolerat...
Background and objective Dose-finding, aiming at finding the maximum tolerated dose, and pharmaco...
International audienceThe aim of phase I clinical trials is to obtain reliable information on safety...
International audiencePhase I dose-finding trials in oncology seek to find the maximum tolerated dos...
The primary objective of phase I dose-finding trials is to determine the maximum tolerated dose (MTD...
International audienceIn early phase dose-finding cancer studies, the objective is to determine the ...
The study of the pharmacokinetic (PK) behavior of a compound is crucial to understand the absorbtion...
A Bayesian adaptive design is proposed for dose-finding in phase I/II clinical trials to incorporate...
In oncology field, early phase clinical trial designs have attracted the interest of clinicians and ...
Abstract Pharmacokinetic (PK) parameter estimation is a critical and complex step in the model‐infor...
Phase I clinical trials aim to find the maximum tolerated dose of an experimental drug. We consider ...
We present a Bayesian adaptive design for dose finding of a combination of two drugs in cancer phase...
Bayesian estimation of pharmacokinetic parameters (PKP), as discussed in this review, provides a pow...
We consider the problem of how to efficiently and safely design dose finding studies. Both current a...
Biopharmaceuticals, especially monoclonal antibodies, have been increasingly used to treat several c...
International audienceBackground and objective - Dose-finding, aiming at finding the maximum tolerat...
Background and objective Dose-finding, aiming at finding the maximum tolerated dose, and pharmaco...
International audienceThe aim of phase I clinical trials is to obtain reliable information on safety...
International audiencePhase I dose-finding trials in oncology seek to find the maximum tolerated dos...
The primary objective of phase I dose-finding trials is to determine the maximum tolerated dose (MTD...
International audienceIn early phase dose-finding cancer studies, the objective is to determine the ...
The study of the pharmacokinetic (PK) behavior of a compound is crucial to understand the absorbtion...
A Bayesian adaptive design is proposed for dose-finding in phase I/II clinical trials to incorporate...
In oncology field, early phase clinical trial designs have attracted the interest of clinicians and ...
Abstract Pharmacokinetic (PK) parameter estimation is a critical and complex step in the model‐infor...
Phase I clinical trials aim to find the maximum tolerated dose of an experimental drug. We consider ...
We present a Bayesian adaptive design for dose finding of a combination of two drugs in cancer phase...
Bayesian estimation of pharmacokinetic parameters (PKP), as discussed in this review, provides a pow...
We consider the problem of how to efficiently and safely design dose finding studies. Both current a...
Biopharmaceuticals, especially monoclonal antibodies, have been increasingly used to treat several c...